IL-YANG FLU Vaccine Prefilled Syringe INJ (influenza virus vaccine quadrivalent) / IL-Yang Pharm - LARVOL DELTA

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (clinicaltrials.gov) - P3 | N=245 | Recruiting | Sponsor: Il-Yang Pharm. Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Respiratory Diseases

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (clinicaltrials.gov) - P3 | N=245 | Not yet recruiting | Sponsor: Il-Yang Pharm. Co., Ltd. | Trial primary completion date: Apr 2024 ➔ Feb 2025

Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (clinicaltrials.gov) - P3 | N=245 | Not yet recruiting | Sponsor: Il-Yang Pharm. Co., Ltd. | Trial completion date: Dec 2023 ➔ Jun 2025 | Trial primary completion date: Aug 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (clinicaltrials.gov) - P3; N=245; Not yet recruiting; Sponsor: Il-Yang Pharm. Co., Ltd.; Trial completion date: Dec 2022 ➔ Dec 2023; Trial primary completion date: Aug 2022 ➔ Aug 2023

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases